A partnership between health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) and Australia’s UniQuest Pty Limited aimed at furthering research and development of a soluble gel is working toward a novel means of delivering cannabinoids to the central nervous system directly from the nasal cavity in order to treat pain, inflammation, seizures and neurological disorders. The partnership is taking advantage of the growing legalization of medical marijuana throughout the world amid increasing evidence of cannabinoids’ benefits. An article discussing this reads: “The global nasal drug delivery technology market is projected to reach $64 billion by 2021, expanding at a compound annual growth rate of 6.5 percent, according to a report issued by MarketsandMarkets (http://ibn.fm/miHWc). While the report is segmented based on dosage form, therapeutic application, end user, system, container and region, it also states ‘intranasal drug delivery is one of the most preferred drug delivery routes among patients as well as healthcare providers.’”
To view the full article, visit http://ibn.fm/57NEQ
Let us hear your thoughts: PreveCeutical Medical Inc. Message Board
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information, visit the company’s website at www.PreveCeutical.com
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.